Clinigen Group has made a deal with Cumberland Pharmaceuticals to market another product in the US, this time an oncology drug Totect (dexrazoxane hydrochloride).
Clinigen and Cumberland enter into a partnership in 2015, and made a U.S. marketing deal for Ethyol (amifostine) in September 2016.
Describing Totect
Totect is an FDA-approved emergency oncology intervention which is indicated to reverse the toxic effects of anthracycline chemotherapy in case of extravasation, which occurs when an injected drug escapes the blood vessels and travels in the body. Totect can reverse caused damage without the need for additional surgeries and procedures.
Clinigen gave Cumberland an exclusive U.S. license for Totect in the U.S. , while Clinigen will produce the drug and deal with the regulatory and clinical management. Totect should be launched in the U.S. later this year.
Totect was acquired by Clinigen’s Specialty Pharmaceuticals (SP) division in 2016 to expand its dexrazoxane portfolio and enter the U.S. market.
Shaun Chilton, Chief Executive Officer of Clinigen said that Cumberland will help spread its dexrazoxane portfolio in the attractive U.S. market. CEO of Cumberland, A.J. Kazimi, noted that the partnership with Clinigen shows good results with already second product becoming a part of the deal. “We are keen to help yet another group of oncology patients with Totect, which reflects our mission of delivering products that help improve patients’ quality of care,” Kazimi said.